DRUG · Bright Minds Biosciences Inc. · Investor Relations

$50.44 -4.76 (-8.62%)

Russell 2000 member Rebalance outlook locked

Market Cap

$544.50M

9.86M

Volume · Oct 21 156.36K Avg daily vol (3M) 143.67K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-06-03	Jefferies Global Healthcare Conference	Conference
2026-03-04	TD Cowen 46th Annual Health Care Conference	Conference
2026-01-06	Topline results for Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy	Earnings call
2025-11-17	Jefferies Global Healthcare Conference in London	Conference
2025-11-12	Guggenheim 2nd Annual Healthcare Innovation Conference	Conference
2025-11-06	Bright Minds Prader-Willi Syndrome (PWS) Program KOL Event	Event
2025-06-05	2025 Jefferies Global Healthcare Conference	Conference
2025-05-21	Bright Minds Biosciences Absence Epilepsy R&D Day	Webcast
2025-03-03	TD Cowen 45th Annual Health Care Conference	Conference
2024-12-10	American Epilepsy Society 2024 Annual Meeting	Shareholder meeting
2024-11-07	Chicago BioCapital Summit	Event
2024-11-06	Bio-Europe	Event
2024-10-09	Society for Neuroscience Annual Meeting	Webcast
2024-09-25	Bright Minds Biosciences BMB-101 Phase 2 study Announcement & KOL Event	Event

Source: https://investors.brightmindsbio.com/

Key facts CIK 1827401 CUSIP 10919W405 13F (30d) 7 filings 7 filers Visit website Investor relations